今日暗盤 | 堃博醫療超購10倍,一手中籤率6.58%
堃博醫療 (02216) 公佈招股結果。內地肺病醫療公司堃博醫療以每股18.7元定價,爲招股價範圍17.2元至18.7元的上限定價,集資淨額15.5億元,一手中籤率6.58%,抽16手(8000股)可穩獲一手。堃博醫療將於9月24日掛牌。
堃博醫療於香港公開發售部分共得近3.1萬人認購,超額認購10.1倍;國際發售部分超額認購3.1倍。
所得款項淨額的49.9%分配予其核心產品,爲InterVapor及RF-II正在進行及計劃的研發和商業上市提供資金;18.5%分配予其他產品及候選產品;9.2%爲繼續擴大其生產廠房的生產線提供資金;13.2%爲通過潛在收購持續擴大產品組合提供資金;9.2%用於營運資金及其他一般公司用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.